Caption Management, LLC Protagonist Therapeutics, Inc Transaction History

Caption Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$18.02 - $29.36 $340,523 - $554,815	18,897 Added 7776.54%	19,140 $528,000
Q1 2023 May 15, 2023	SELL	$10.78 - $25.38 $428,580 - $1.01 Million	-39,757 Reduced 99.39%	243 $5,000
Q3 2022 Nov 14, 2022	BUY	$7.86 - $11.71 $232,656 - $346,616	29,600 Added 284.62%	40,000 $337,000
Q2 2022 Aug 15, 2022	SELL	$7.06 - $25.52 $420,776 - $1.52 Million	-59,600 Reduced 85.14%	10,400 $82,000
Q1 2022 May 13, 2022	SELL	$23.34 - $36.08 $2.86 Million - $4.43 Million	-122,702 Reduced 63.67%	70,000 $1.66 Million
Q4 2021 Feb 11, 2022	BUY	$17.63 - $37.1 $1.46 Million - $3.07 Million	82,702 Added 75.18%	192,702 $6.59 Million
Q3 2021 Nov 12, 2021	BUY	$12.95 - $49.69 $1.42 Million - $5.47 Million	110,000 New	110,000 $1.95 Million

212

59.1M

19K

107K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.25B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.